Penumbra Announces Key Events at Society of Interventional Radiology 2017 Meeting

. (NYSE: PEN), a global healthcare company focused on
interventional therapies, today announced key events at the upcoming
Society of Interventional Radiology 2017 meeting (SIR 2017) to be held
March 4-9 at the Washington Convention Center in Washington, D.C. These
events include results of a single-center study of the company’s Indigo®
System, in-booth presentations and workshop demonstrations of the
company’s peripheral vascular products for thrombectomy and embolization.

Corey Teigen, M.D., Sanford Health, Fargo, ND, will share results of a
study of 43 patients comparing use of mechanical thrombectomy by
aspiration using the Indigo System to intra-arterial thrombolytics in
patients with peripheral or visceral arterial occlusions or emboli.
“Rapid Reperfusion from Mechanical Aspiration Thrombectomy is Superior
to Slow Infusion of Intra-Arterial Thrombolytics in Patients with
Confirmed Peripheral or Visceral Arterial Occlusions” (abstract #253)
will be presented during the Thromboembolic Disease and Lysis scientific
session (SS27) on Tuesday, March 7 from 3-3:09 p.m. in Room 150A.

Attendees will have the opportunity to learn more about Penumbra’s
Indigo System, Ruby® Coil, POD® System and LANTERN®
devices, as well as the Penumbra System®, at the following

  • Dr. Teigen will also present the results of a subset of 67 patients in
    the Aneurysm Coiling Efficiency (ACE) Study at Penumbra Booth #541 on
    Tuesday, March 7 at 10 a.m. The goal of this multi-center study was to
    collect long-term outcomes of aneurysms and vessels embolized
    utilizing soft, large volume coils to achieve high packing density.
  • A dinner symposium on Tuesday, March 7 at 6:30 p.m. at the Archives
    at the Marriott Marquis. James Benenati, M.D., Miami Cardiac and
    Vascular Institute
    , FL, and Parag Patel, M.D., Medical College of
    , will share their experience with Penumbra’s peripheral
    vascular products.
  • Three in-booth sessions at Penumbra Booth #541 on Monday, March 6, and
    Tuesday, March 7, will provide attendees with opportunities to hear
    from physician experts regarding the application of Penumbra’s
    peripheral technologies in their practice.
  • Four workshops will offer attendees additional discussion
    opportunities with experienced users and hands-on experience with
    Penumbra embolization and thrombectomy products in simulated models:
    Atherectomy & Thrombectomy (Location – HO08) and Catheters &
    Microcatheters (Location – HO01) Workshop on Sunday, March 5; Coils
    and Plugs (Location – HO02) Workshop on Tuesday, March 7; and IVC
    Filters (Location – HO10) on Wednesday, March 8.
  • Penumbra’s aspiration-based thrombectomy system for acute ischemic
    stroke revascularization will be featured during the day-long SIR: The
    Stroke Course on Thursday, March 9 in Room 151AB. The course includes
    hands-on workshops with the Penumbra System with ACE TM 68
    Reperfusion Catheter.

About Penumbra’s Peripheral Vascular Products

Penumbra has a growing suite of thrombectomy and embolization products
for use in a range of peripheral vascular conditions:

  • The Indigo System is a next-generation continuous aspiration
    thrombectomy device designed for the removal of fresh, soft emboli and
    thrombi from the peripheral venous and arterial systems, and includes
    four catheter sizes (CAT 3, 5, 6 and 8). The aspiration lumen is
    paired with a proprietary continuous vacuum aspiration pump to
    evacuate clot. The Indigo System’s proprietary SeparatorTM
    technology enables unobstructed aspiration for the duration of the
    procedure. The Indigo System, received 510(k) clearance in May 2015 to
    remove clots from the peripheral venous system, and it is one of the
    newest interventional advancements designed specifically to help
    physicians remove DVTs.
  • Penumbra’s embolization platform includes RUBY® Coil; POD®
    (Penumbra Occlusion Device), designed specifically to occlude
    peripheral vessels; and POD Packing Coil, which is uniquely designed
    to pack very densely behind Ruby and POD to occlude arteries and veins
    throughout the peripheral vasculature, including aneurysms.
  • The LANTERN microcatheter is designed to assist in the delivery of
    diagnostic agents, such as contrast media, and therapeutic devices,
    such as occlusion coils, to the peripheral vasculature. It is offered
    in a variety of lengths and tip shapes.

About Penumbra System

The Penumbra System enables physicians to use aspiration, which acts
like a minimally invasive “vacuum” inside the artery, to remove
stroke-causing blood clots from the brain. The Penumbra System is the
only FDA-cleared integrated aspiration system for the revascularization
of acute ischemic stroke patients with large vessel occlusions.

Important Safety Information

Additional information about Penumbra’s products can be located on
Penumbra’s website at
Prior to use, please refer to Instructions for Use for complete product
indications, contraindications, warnings, precautions, potential adverse
events and detailed instructions for use.

About Penumbra

Penumbra, Inc., headquartered in Alameda, California, is a global
healthcare company focused on interventional therapies that designs,
develops, manufactures and markets innovative devices. The company has a
broad portfolio of products that addresses challenging medical
conditions and significant clinical needs across two major markets,
neuro and peripheral vascular. Penumbra sells its products to hospitals
primarily through its direct sales organization in the U.S., most of
Europe, Canada and Australia, and through distributors in select
international markets. Penumbra and the Penumbra logo are trademarks of
Penumbra, Inc. Penumbra, the Penumbra logo, Indigo, Ruby, POD, LANTERN,
Pump MAX, Penumbra System and ACE are trademarks of Penumbra, Inc. Other
trademarks are the property of their respective owners.

Forward-Looking Statements

Except for historical information, certain statements in this press
release are forward-looking in nature and are subject to risks,
uncertainties and assumptions about us. Our business and operations are
subject to a variety of risks and uncertainties and, consequently,
actual results may differ materially from those projected by any
forward-looking statements. Factors that could cause actual results to
differ from those projected include, but are not limited to: failure to
sustain or grow profitability or generate positive cash flows; failure
to effectively introduce and market new products; delays in product
introductions; significant competition; inability to further penetrate
our current customer base, expand our user base and increase the
frequency of use of our products by our customers; inability to achieve
or maintain satisfactory pricing and margins; manufacturing
difficulties; permanent write-downs or write-offs of our inventory;
product defects or failures; unfavorable outcomes in clinical trials;
inability to maintain our culture as we grow; fluctuations in foreign
currency exchange rates; and potential adverse regulatory actions. These
risks and uncertainties, as well as others, are discussed in greater
detail in our filings with the Securities and Exchange Commission,
including our Quarterly Reports on Form 10-Q and our Annual Report on
Form 10-K for the year ended December 31, 2016. There may be additional
risks of which we are not presently aware or that we currently believe
are immaterial which could have an adverse impact on our business. Any
forward-looking statements are based on our current expectations,
estimates and assumptions regarding future events and are applicable
only as of the dates of such statements. We make no commitment to revise
or update any forward-looking statements in order to reflect events or
circumstances that may change.

Source: Penumbra, Inc.

Source: Penumbra, Inc.

Merryman Communications

Betsy Merryman, 310-560-8176